CL2013001001A1 - Composicion farmaceutica que comprende el acido (4-{4-[5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclohexil)-acetico, tensoactivos, aglutinantes secos con propiedades desintegrantes, rellenos y desintegrantes; proceso de preparacion y uso en un trastorno asociado a dgat1. - Google Patents

Composicion farmaceutica que comprende el acido (4-{4-[5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclohexil)-acetico, tensoactivos, aglutinantes secos con propiedades desintegrantes, rellenos y desintegrantes; proceso de preparacion y uso en un trastorno asociado a dgat1.

Info

Publication number: CL2013001001A1
Authority: CL; Chile
Prior art keywords: pyridin; disintegrating; acid; dgat1; trifluoro
Prior art date: 2010-10-14

Application number

CL2013001001A

Other languages

English (en)

Inventor

Hong Weng

Natrajan Kumaraperumal

Ricard Nause

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-14

Filing date

2013-04-12

Publication date

2013-10-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44908106&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013001001(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-04-12 Application filed by Novartis Ag filed Critical Novartis Ag

2013-10-25 Publication of CL2013001001A1 publication Critical patent/CL2013001001A1/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Inorganic Chemistry (AREA)
Obesity (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Child & Adolescent Psychology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Biochemistry (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

CL2013001001A 2010-10-14 2013-04-12 Composicion farmaceutica que comprende el acido (4-{4-[5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclohexil)-acetico, tensoactivos, aglutinantes secos con propiedades desintegrantes, rellenos y desintegrantes; proceso de preparacion y uso en un trastorno asociado a dgat1. CL2013001001A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US39310310P	2010-10-14	2010-10-14

Publications (1)

Publication Number	Publication Date
CL2013001001A1 true CL2013001001A1 (es)	2013-10-25

Family

ID=44908106

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013001001A CL2013001001A1 (es)	2010-10-14	2013-04-12	Composicion farmaceutica que comprende el acido (4-{4-[5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclohexil)-acetico, tensoactivos, aglutinantes secos con propiedades desintegrantes, rellenos y desintegrantes; proceso de preparacion y uso en un trastorno asociado a dgat1.

Country Status (30)

Country	Link
US (5)	US20130190354A1 (es)
EP (1)	EP2627319B1 (es)
JP (1)	JP6060081B2 (es)
KR (1)	KR20130100311A (es)
CN (1)	CN103179957B (es)
AR (1)	AR083417A1 (es)
AU (1)	AU2011316003B2 (es)
BR (1)	BR112013008757A2 (es)
CA (1)	CA2813781C (es)
CL (1)	CL2013001001A1 (es)
CO (1)	CO6710915A2 (es)
DK (1)	DK2627319T3 (es)
EC (1)	ECSP13012755A (es)
ES (1)	ES2712064T3 (es)
GT (1)	GT201300096A (es)
HU (1)	HUE043524T2 (es)
IL (1)	IL225434A0 (es)
MA (1)	MA34599B1 (es)
MX (1)	MX2013004162A (es)
NZ (1)	NZ608558A (es)
PE (1)	PE20140375A1 (es)
PH (1)	PH12013500695A1 (es)
PL (1)	PL2627319T3 (es)
PT (1)	PT2627319T (es)
RU (1)	RU2595866C2 (es)
SG (1)	SG189078A1 (es)
SI (1)	SI2627319T1 (es)
TR (1)	TR201902435T4 (es)
WO (1)	WO2012051488A1 (es)
ZA (1)	ZA201302108B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR083417A1 (es)	2010-10-14	2013-02-21	Novartis Ag	Composiciones farmaceuticas que contienen un dgat1 inhibidor
WO2013055910A1 (en)	2011-10-12	2013-04-18	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2841432A1 (en) *	2012-04-27	2015-03-04	Novartis AG	Tetrahydropyran dgat1 inhibitors
WO2013169648A1 (en) *	2012-05-07	2013-11-14	Novartis Ag	Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
WO2014074668A1 (en)	2012-11-08	2014-05-15	Arena Pharmaceuticals, Inc.	Modulators of gpr119 and the treatment of disorders related thereto
BR112017019358A2 (pt)	2015-03-13	2018-05-08	Esperion Therapeutics Inc	combinações e formulações de dose fixa compreendendo etc1002 e ezetimiba e métodos de tratamento ou redução do risco de doença cardiovascular
MA41793A (fr)	2015-03-16	2018-01-23	Esperion Therapeutics Inc	Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
TWI711464B (zh)	2015-11-19	2020-12-01	欣耀生醫股份有限公司	預防或治療脂肪肝、保護肝功能、或改善脂肪肝引起的肝病變或其他相關病症之組合物及方法
US11883404B2 (en)	2016-03-04	2024-01-30	Taiho Pharmaceuticals Co., Ltd.	Preparation and composition for treatment of malignant tumors
KR102793563B1 (ko)	2016-03-04	2025-04-11	다이호야쿠힌고교 가부시키가이샤	악성 종양 치료용 제제 및 조성물
US20180338922A1 (en) *	2017-05-26	2018-11-29	Esperion Therapeutics, Inc.	Fixed dose formulations
US10632092B2 (en)	2017-08-30	2020-04-28	First Fruits Business Ministry, Llc	Composition for and method to increase serum adiponectin and reduce body fat
EP3765012A4 (en)	2018-03-16	2021-12-15	Anji Pharmaceuticals Inc.	COMPOSITIONS AND METHODS OF TREATMENT OF SEVERE CONSTIPATION
RU2759746C1 (ru)	2018-03-19	2021-11-17	Тайхо Фармасьютикал Ко., Лтд.	Фармацевтическая композиция, включающая алкилсульфат натрия

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0861073B1 (en)	1995-11-14	2004-07-28	Abbott GmbH & Co. KG	Stabilized thyroid hormone preparations and methods of making same
GB9613470D0 (en) *	1996-06-27	1996-08-28	Ciba Geigy Ag	Small solid oral dosage form
DE19816070A1 (de) *	1998-04-09	1999-10-14	Aventis Res & Tech Gmbh & Co	Retardtablette hergestellt aus linearen wasserunlöslichen Polysacchariden
IL161996A0 (en) *	2001-12-21	2005-11-20	Pfizer Prod Inc	Directly compressible formulations of azithromycin
CA2605300A1 (en) *	2005-04-19	2006-10-26	Bayer Pharmaceuticals Corporation	Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
KR101219042B1 (ko) *	2005-12-06	2013-01-07	삼성디스플레이 주식회사	반투과형 액정 표시 장치
JP5165582B2 (ja) *	2005-12-16	2013-03-21	メルク・シャープ・エンド・ドーム・コーポレイション	ジペプチジルペプチダーゼ−４インヒビターとメトホルミンとを組み合わせた医薬組成物
AU2007223278A1 (en)	2006-03-06	2007-09-13	Wyeth	Tablet formulations and processes
US20070224258A1 (en)	2006-03-22	2007-09-27	Bunick Frank J	Dosage forms having a randomized coating
ES2649564T3 (es) *	2006-03-31	2018-01-12	Novartis Ag	Inhibidores de DGAT
SG177144A1 (en)	2006-11-29	2012-01-30	Abbott Lab	Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
US20080145425A1 (en) *	2006-12-15	2008-06-19	Pliva Research & Development Limited	Pharmaceutical composition of zolpidem
CN101743234A (zh)	2007-04-30	2010-06-16	雅培制药有限公司	二酰甘油o-酰基转移酶1型酶的抑制剂
US8283331B2 (en) *	2007-10-09	2012-10-09	Children's Medical Center Corporation	Methods to regulate miRNA processing by targeting Lin-28
HUE033494T2 (en) *	2009-03-31	2017-12-28	Ligand Pharm Inc	Biphenylsulfonamide Endothelin and Angiotensin II Receptor Antagonist for Glomerulosclerosis
ES2586127T3 (es) *	2010-03-30	2016-10-11	Novartis Ag	Usos de inhibidores de DGAT1
AR083417A1 (es)	2010-10-14	2013-02-21	Novartis Ag	Composiciones farmaceuticas que contienen un dgat1 inhibidor

2011
- 2011-10-13 AR ARP110103797A patent/AR083417A1/es unknown
- 2011-10-14 RU RU2013121795/15A patent/RU2595866C2/ru active
- 2011-10-14 SI SI201131677T patent/SI2627319T1/sl unknown
- 2011-10-14 CN CN201180049179.4A patent/CN103179957B/zh active Active
- 2011-10-14 MX MX2013004162A patent/MX2013004162A/es not_active Application Discontinuation
- 2011-10-14 JP JP2013534025A patent/JP6060081B2/ja active Active
- 2011-10-14 HU HUE11779278A patent/HUE043524T2/hu unknown
- 2011-10-14 SG SG2013021944A patent/SG189078A1/en unknown
- 2011-10-14 TR TR2019/02435T patent/TR201902435T4/tr unknown
- 2011-10-14 PE PE2013000837A patent/PE20140375A1/es not_active Application Discontinuation
- 2011-10-14 PH PH1/2013/500695A patent/PH12013500695A1/en unknown
- 2011-10-14 PL PL11779278T patent/PL2627319T3/pl unknown
- 2011-10-14 DK DK11779278.8T patent/DK2627319T3/en active
- 2011-10-14 AU AU2011316003A patent/AU2011316003B2/en not_active Ceased
- 2011-10-14 MA MA35806A patent/MA34599B1/fr unknown
- 2011-10-14 ES ES11779278T patent/ES2712064T3/es active Active
- 2011-10-14 NZ NZ608558A patent/NZ608558A/en not_active IP Right Cessation
- 2011-10-14 EP EP11779278.8A patent/EP2627319B1/en active Active
- 2011-10-14 WO PCT/US2011/056275 patent/WO2012051488A1/en active Application Filing
- 2011-10-14 CA CA2813781A patent/CA2813781C/en active Active
- 2011-10-14 BR BR112013008757-9A patent/BR112013008757A2/pt not_active IP Right Cessation
- 2011-10-14 PT PT11779278T patent/PT2627319T/pt unknown
- 2011-10-14 US US13/825,919 patent/US20130190354A1/en not_active Abandoned
- 2011-10-14 KR KR1020137009333A patent/KR20130100311A/ko not_active Withdrawn
2013
- 2013-03-20 ZA ZA2013/02108A patent/ZA201302108B/en unknown
- 2013-03-21 IL IL225434A patent/IL225434A0/en unknown
- 2013-04-11 GT GT201300096A patent/GT201300096A/es unknown
- 2013-04-11 CO CO13094273A patent/CO6710915A2/es not_active Application Discontinuation
- 2013-04-12 EC ECSP13012755 patent/ECSP13012755A/es unknown
- 2013-04-12 CL CL2013001001A patent/CL2013001001A1/es unknown
2015
- 2015-07-22 US US14/805,919 patent/US20150320687A1/en not_active Abandoned
2016
- 2016-09-12 US US15/262,056 patent/US20160374947A1/en not_active Abandoned
2018
- 2018-05-01 US US15/968,104 patent/US10646446B2/en active Active
2020
- 2020-03-31 US US16/835,921 patent/US11304907B2/en active Active

Also Published As

Publication number	Publication date
ES2712064T3 (es)	2019-05-09
RU2013121795A (ru)	2014-11-20
PT2627319T (pt)	2019-02-27
US20150320687A1 (en)	2015-11-12
PL2627319T3 (pl)	2019-05-31
US20200230062A1 (en)	2020-07-23
BR112013008757A2 (pt)	2020-09-01
CO6710915A2 (es)	2013-07-15
JP6060081B2 (ja)	2017-01-11
AU2011316003B2 (en)	2015-03-19
EP2627319B1 (en)	2018-11-21
US20130190354A1 (en)	2013-07-25
CN103179957B (zh)	2016-05-18
SG189078A1 (en)	2013-05-31
AU2011316003A1 (en)	2013-04-11
US20180243222A1 (en)	2018-08-30
DK2627319T3 (en)	2019-03-18
CA2813781A1 (en)	2012-04-19
ECSP13012755A (es)	2014-01-31
AR083417A1 (es)	2013-02-21
JP2013539794A (ja)	2013-10-28
RU2595866C2 (ru)	2016-08-27
NZ608558A (en)	2015-03-27
GT201300096A (es)	2014-07-08
CA2813781C (en)	2018-08-07
MA34599B1 (fr)	2013-10-02
IL225434A0 (en)	2013-06-27
EP2627319A1 (en)	2013-08-21
US10646446B2 (en)	2020-05-12
WO2012051488A1 (en)	2012-04-19
HUE043524T2 (hu)	2019-08-28
MX2013004162A (es)	2014-12-08
ZA201302108B (en)	2013-11-27
US11304907B2 (en)	2022-04-19
KR20130100311A (ko)	2013-09-10
SI2627319T1 (sl)	2019-04-30
PE20140375A1 (es)	2014-03-19
TR201902435T4 (tr)	2019-03-21
PH12013500695A1 (en)	2017-08-09
US20160374947A1 (en)	2016-12-29
CN103179957A (zh)	2013-06-26

Publication	Publication Date	Title
CL2013001001A1 (es)	2013-10-25	Composicion farmaceutica que comprende el acido (4-{4-[5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclohexil)-acetico, tensoactivos, aglutinantes secos con propiedades desintegrantes, rellenos y desintegrantes; proceso de preparacion y uso en un trastorno asociado a dgat1.
EP3077447A4 (en)	2017-08-16	A composition in the form of a lignin polyol, a method for the production thereof and use thereof
BR112014028755A2 (pt)	2018-04-24	composição de argamassa de poliuretano, processo para preparação da composição de argamassa de poliuretano, e, uso de uma composição de argamassa de poliuretano.
PT2892808T (pt)	2018-06-14	Agregados estabilizados e outros materiais e estruturas para fins que incluem absorção de energia mas que não estão limitados à mesma
PL2689003T3 (pl)	2021-04-06	Proces wytwarzania etanolu z mieleniem na sucho i układ ze sposobem mielenia w fazie początkowej
CL2013000052A1 (es)	2013-10-04	Proceso para la produccion de lignina precipitada a partir de licor negro; lignina precipitada; solucion que comprende a dicha lignina precipitada; y uso de dicha lignina precipitada.
CL2007001972A1 (es)	2008-04-04	Ester isopropilico del acido 4-[6-(6-metanosulfonil-2-metilpiridin-3-ilamino)-5-metilpirimidin-4-iloxi]piperidin-1-carboxilico, moduladores del metabolismo; composicion farmaceutica; y su uso para tratar trastornos metabolicos.
EP2764516A4 (en)	2015-07-08	SELF-HISTORIZATION AND HIERARCHICAL CONSISTENCY FOR NON-VOLATILE STORES
BRPI1006449A2 (pt)	2016-02-10	composição de poliol estável em armazenamento, formulação para o preparo de uma espuma de poliisocianurato e método para o preparo de uma espuma de poliisocianurato
PL2601252T3 (pl)	2016-05-31	Nanokompozyt polimerowy zawierający kwas polimlekowy wzmocniony zmodyfikowanym filokrzemianem
BR112014029717A2 (pt)	2017-06-27	material lignocelulósico, tendo um núcleo e duas camadas exteriores, método para produzir o mesmo e uso do material lignocelulósico.
BR112014003040A2 (pt)	2017-03-21	mistura de polímero em uma forma sólida ou aquosa, composição, e, uso de misturas de polímero.
BR112015013874A2 (pt)	2017-07-11	métodos e composição para o tratamento hidrocatalítico hidrotérmico de biomassa na produção de hidrocarbonetos superiores apropriados para uso em combustíveis de transporte e produtosquímicos industriais a partir de biomassa
Christofides et al.	2013	Conditional demimartingales and related results
CL2013000929A1 (es)	2013-09-27	Forma cristalina c de la sal sodica del acido (4-(4-(5-(6-trifluoro metil piridin-3-il-amino) piridin-2-il-) fenil)-ciclohexil)-acetico; proceso de preparacion; composicion farmaceutica que lo comprende; y su uso para el tratamiento de un trastorno asociado con la actividad del dagt.
BR112013015005A2 (pt)	2016-08-09	corpo moldado contendo lignocelulose em multicamadas, processo para sua produção, e, uso do corpo moldado
ZA201405333B (en)	2017-11-29	Lignocellulosic materials with lignocellulosic fibers in the outer layers and expanded plastics particles present in the core, and process and use thereof
CL2013000089A1 (es)	2013-03-08	Tableta de desintegracion rapida en la cavidad oral que contiene particulas nucleares con acido 2-(3-ciano-4-isobutiloxifenil)-4-metil-5-tiazolcarboxilico y que estan recubiertas con dos capas.
MX2012007630A (es)	2012-08-01	Incremento de volumen para material colocado por aire.
EP2557151A4 (en)	2014-02-19	S-ADENOSYL-L-METHIONINE-CONTAINING DRYING COMPOSITION WITH EXCELLENT STORAGE STABILITY AND METHOD OF MANUFACTURING THEREOF
刘凯 et al.	2012	Influence Factor of Thermal Conductivity of Cement Concrete and ItsPrediction Model
SG2013085709A (en)	2014-07-30	New process for the synthesis of 3-(2-bromo-4,5-dimethoxyphenyl)propanenitrile, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
HRP20182061T1 (hr)	2019-02-08	4-{4-[(1e)-4-(2,9-diazaspiro[5.5]undec-2-il)but-1-en-1-il]-2-metilbenzil}-5-(propan-2-il)-1h-pirazol-3-il-beta-d-glukopiranozid-acetat
GB201405031D0 (en)	2014-05-07	Storage stable premixed hydraulic cement compositions, cements, methods, and articles
PL3004468T3 (pl)	2018-02-28	Sposób budowy fundamentów pasywnych ograniczający ubytki ciepła z budynku, jak również koszty wykonania i zużycie materiałów